Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study
2007

Efficacy and safety of tiotropium in COPD patients in primary care

Sample size: 374 publication 10 minutes Evidence: moderate

Author Information

Author(s): Daryl Freeman, Angela Lee, David Price

Primary Institution: University of Aberdeen

Hypothesis

Does tiotropium improve lung function and reduce exacerbations in COPD patients managed in primary care?

Conclusion

Tiotropium provides additional benefits to usual primary care management in a representative COPD population.

Supporting Evidence

  • Tiotropium improved lung function as measured by FEV1 and FVC.
  • Patients on tiotropium had fewer COPD exacerbations compared to those on placebo.
  • Rescue medication use was significantly lower in the tiotropium group.

Takeaway

This study found that a medication called tiotropium helps people with breathing problems feel better and have fewer bad days.

Methodology

A randomized, placebo-controlled, parallel-group, 12-week study across 44 primary care centers.

Potential Biases

Potential bias due to the exclusion of patients with significant comorbidities.

Limitations

The study duration was short, and the sample size may limit the generalizability of the findings.

Participant Demographics

Patients aged 40 and older with a history of smoking and COPD, including a range of disease severities.

Statistical Information

P-Value

0.0102

Confidence Interval

95% CI: 0.01 L, 0.10 L

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1465-9921-8-45

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication